Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter, Retrospective, Observational Study of Icotinib for Post-Surgical Adjuvant Therapy in Stage IA2 High-Risk to IB Non-Small-Cell Lung Cancer With Positive EGFR-Sensitive Mutations

NCT07806604 is registered in ClinicalTrials.gov with Betta Pharmaceuticals Co., Ltd. as lead sponsor.

NCT NCT07806604
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07806604 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter, Retrospective, Observational Study of Icotinib for Post-Surgical Adjuvant Therapy in Stage IA2 High-Risk to IB Non-Small-Cell Lung Cancer With Positive EGFR-Sensitive Mutations
Lead sponsor
Betta Pharmaceuticals Co., Ltd.
Phase
Observational
Overall status
Recruiting
Start date
September 30, 2026
Completion date
June 30, 2027
Enrollment
2,572 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

nsclc (non-small cell lung cancer)